Nicholas M Anstey1, Tsin W Yeo1, Matthew J Grigg1, Timothy William1, Jayaram Menon1, Prabakaran Dhanaraj1, Bridget E Barber1, Christopher S Wilkes1, Lorenz von Seidlein1, Giri S Rajahram1, Cielo Pasay1, James S McCarthy1, Ric N Price1. 1. Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia (M J Grigg MBBS, B E Barber FRACP, C S Wilkes MBBS, L von Seidlein MD, Prof R N Price FRCP, Prof N M Anstey FRACP, T W Yeo PhD); Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Kota Kinabalu, Sabah, Malaysia (T William FRCP, G S Rajahram MRCP, M J Grigg, B E Barber, C S Wilkes, Prof N M Anstey, T W Yeo); Sabah Department of Health and Queen Elizabeth Hospital, Clinical Research Centre, Kota Kinabalu, Sabah, Malaysia (T William, J Menon FRCP, P Dhanaraj MBBS, G S Rajahram) (L von Seidlein); Queensland Institute of Medical Research, University of Queensland, St Lucia, QLD, Australia (Prof J S McCarthy FRACP, C Pasay PhD); Jesselton Medical Centre, Kota Kinabalu, Sabah, Malaysia (T William); Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (Prof R N Price); Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore (T W Yeo); and Communicable Disease Centre, Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore (T W Yeo).
Abstract
BACKGROUND: The zoonotic parasite Plasmodium knowlesi has become the most common cause of human malaria in Malaysia and is present throughout much of southeast Asia. No randomised controlled trials have been done to identify the optimum treatment for this emerging infection. We aimed to compare artesunate-mefloquine with chloroquine to define the optimum treatment for uncomplicated P knowlesi malaria in adults and children. METHODS: We did this open-label, randomised controlled trial at three district hospitals in Sabah, Malaysia. Patients aged 1 year or older with uncomplicated P knowlesi malaria were randomly assigned, via computer-generated block randomisation (block sizes of 20), to receive oral artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine) or chloroquine (target dose 25 mg/kg). Research nursing staff were aware of group allocation, but allocation was concealed from the microscopists responsible for determination of the primary endpoint, and study participants were not aware of drug allocation. The primary endpoint was parasite clearance at 24 h. Analysis was by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT01708876. FINDINGS: Between Oct 16, 2012, and Dec 13, 2014, we randomly assigned 252 patients to receive either artesunate-mefloquine (n=127) or chloroquine (n=125); 226 (90%) patients comprised the modified intention-to-treat population. 24 h after treatment, we recorded parasite clearance in 97 (84% [95% CI 76-91]) of 115 patients in the artesunate-mefloquine group versus 61 (55% [45-64]) of 111 patients in the chloroquine group (difference in proportion 29% [95% CI 18·0-40·8]; p<0·0001). Parasite clearance was faster in patients given artesunate-mefloquine than in those given chloroquine (18·0 h [range 6·0-48·0] vs 24·0 h [6·0-60·0]; p<0·0001), with faster clearance of ring stages in the artesunate-mefloquine group (mean time to 50% clearance of baseline parasites 8·6 h [95% CI 7·9-9·4] vs 13·8 h [12·1-15·4]; p<0·0001). Risk of anaemia within 28 days was lower in patients in the artesunate-mefloquine group (71 [62%; 95% CI 52·2-70·6]) than in those in the chloroquine group (83 [75%; 65·6-82·5]; p=0·035). Gametocytaemia as detected by PCR for pks25 was present in 44 (86%) of 51 patients in the artesunate-mefloquine group and 41 (84%) of 49 patients in the chloroquine group at baseline, and in three (6%) of 49 patients and two (4%) of 48 patients, respectively, at day 7. Fever clearance was faster in the artesunate-mefloquine group (mean 11·5 h [95% CI 8·3-14·6]) than in the chloroquine group (14·8 h [11·7-17·8]; p=0·034). Bed occupancy was 2426 days per 1000 patients in the artesunate-mefloquine group versus 2828 days per 1000 patients in the chloroquine group (incidence rate ratio 0·858 [95% CI 0·812-0·906]; p<0·0001). One (<1%) patient in the artesunate-mefloquine group had a serious neuropsychiatric event regarded as probably related to study drug. INTERPRETATION:Artesunate-mefloquine is highly efficacious for treatment of uncomplicated P knowlesi malaria. The rapid therapeutic response of the drug offers significant advantages compared with chloroquine monotherapy and supports a unified treatment policy for artemisinin-based combination therapy for all Plasmodium species in co-endemic areas. FUNDING: Malaysian Ministry of Health, Australian National Health and Medical Research Council, and Asia Pacific Malaria Elimination Network.
RCT Entities:
BACKGROUND: The zoonotic parasite Plasmodium knowlesi has become the most common cause of humanmalaria in Malaysia and is present throughout much of southeast Asia. No randomised controlled trials have been done to identify the optimum treatment for this emerging infection. We aimed to compare artesunate-mefloquine with chloroquine to define the optimum treatment for uncomplicated P knowlesi malaria in adults and children. METHODS: We did this open-label, randomised controlled trial at three district hospitals in Sabah, Malaysia. Patients aged 1 year or older with uncomplicated P knowlesi malaria were randomly assigned, via computer-generated block randomisation (block sizes of 20), to receive oral artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine) or chloroquine (target dose 25 mg/kg). Research nursing staff were aware of group allocation, but allocation was concealed from the microscopists responsible for determination of the primary endpoint, and study participants were not aware of drug allocation. The primary endpoint was parasite clearance at 24 h. Analysis was by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT01708876. FINDINGS: Between Oct 16, 2012, and Dec 13, 2014, we randomly assigned 252 patients to receive either artesunate-mefloquine (n=127) or chloroquine (n=125); 226 (90%) patients comprised the modified intention-to-treat population. 24 h after treatment, we recorded parasite clearance in 97 (84% [95% CI 76-91]) of 115 patients in the artesunate-mefloquine group versus 61 (55% [45-64]) of 111 patients in the chloroquine group (difference in proportion 29% [95% CI 18·0-40·8]; p<0·0001). Parasite clearance was faster in patients given artesunate-mefloquine than in those given chloroquine (18·0 h [range 6·0-48·0] vs 24·0 h [6·0-60·0]; p<0·0001), with faster clearance of ring stages in the artesunate-mefloquine group (mean time to 50% clearance of baseline parasites 8·6 h [95% CI 7·9-9·4] vs 13·8 h [12·1-15·4]; p<0·0001). Risk of anaemia within 28 days was lower in patients in the artesunate-mefloquine group (71 [62%; 95% CI 52·2-70·6]) than in those in the chloroquine group (83 [75%; 65·6-82·5]; p=0·035). Gametocytaemia as detected by PCR for pks25 was present in 44 (86%) of 51 patients in the artesunate-mefloquine group and 41 (84%) of 49 patients in the chloroquine group at baseline, and in three (6%) of 49 patients and two (4%) of 48 patients, respectively, at day 7. Fever clearance was faster in the artesunate-mefloquine group (mean 11·5 h [95% CI 8·3-14·6]) than in the chloroquine group (14·8 h [11·7-17·8]; p=0·034). Bed occupancy was 2426 days per 1000 patients in the artesunate-mefloquine group versus 2828 days per 1000 patients in the chloroquine group (incidence rate ratio 0·858 [95% CI 0·812-0·906]; p<0·0001). One (<1%) patient in the artesunate-mefloquine group had a serious neuropsychiatric event regarded as probably related to study drug. INTERPRETATION:Artesunate-mefloquine is highly efficacious for treatment of uncomplicated P knowlesi malaria. The rapid therapeutic response of the drug offers significant advantages compared with chloroquine monotherapy and supports a unified treatment policy for artemisinin-based combination therapy for all Plasmodium species in co-endemic areas. FUNDING: Malaysian Ministry of Health, Australian National Health and Medical Research Council, and Asia Pacific Malaria Elimination Network.
Authors: James S McCarthy; Paul M Griffin; Silvana Sekuloski; A Taylor Bright; Rebecca Rockett; David Looke; Suzanne Elliott; David Whiley; Theo Sloots; Elizabeth A Winzeler; Katharine R Trenholme Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Bridget E Barber; Timothy William; Matthew J Grigg; Jayaram Menon; Sarah Auburn; Jutta Marfurt; Nicholas M Anstey; Tsin W Yeo Journal: Clin Infect Dis Date: 2012-10-19 Impact factor: 9.079
Authors: Giri S Rajahram; Bridget E Barber; Timothy William; Jayaram Menon; Nicholas M Anstey; Tsin W Yeo Journal: Malar J Date: 2012-08-20 Impact factor: 2.979
Authors: Farrah A Fatih; Henry M Staines; Angela Siner; Mohammed Atique Ahmed; Lu Chan Woon; Erica M Pasini; Clemens Hm Kocken; Balbir Singh; Janet Cox-Singh; Sanjeev Krishna Journal: Malar J Date: 2013-11-19 Impact factor: 2.979
Authors: Sumudu Britton; Qin Cheng; Matthew J Grigg; Timothy William; Nicholas M Anstey; James S McCarthy Journal: Am J Trop Med Hyg Date: 2016-05-09 Impact factor: 2.345
Authors: Rhea J Longley; Matthew J Grigg; Kael Schoffer; Thomas Obadia; Stephanie Hyslop; Kim A Piera; Narimane Nekkab; Ramin Mazhari; Eizo Takashima; Takafumi Tsuboi; Matthias Harbers; Kevin Tetteh; Chris Drakeley; Chetan E Chitnis; Julie Healer; Wai-Hong Tham; Jetsumon Sattabongkot; Michael T White; Daniel J Cooper; Giri S Rajahram; Bridget E Barber; Timothy William; Nicholas M Anstey; Ivo Mueller Journal: Cell Rep Med Date: 2022-06-21
Authors: Matthew J Grigg; Inke N Lubis; Kevin K A Tetteh; Bridget E Barber; Timothy William; Giri S Rajahram; Angelica F Tan; Colin J Sutherland; Rintis Noviyanti; Chris J Drakeley; Sumudu Britton; Nicholas M Anstey Journal: Adv Parasitol Date: 2021-09-17 Impact factor: 3.125
Authors: Bridget E Barber; Matthew J Grigg; Daniel J Cooper; Donelly A van Schalkwyk; Timothy William; Giri S Rajahram; Nicholas M Anstey Journal: Adv Parasitol Date: 2021-09-01 Impact factor: 3.125
Authors: Nicholas M Anstey; Matthew J Grigg; Giri S Rajahram; Daniel J Cooper; Timothy William; Steven Kho; Bridget E Barber Journal: Adv Parasitol Date: 2021-08-28 Impact factor: 3.125
Authors: Steven Kho; Bridget E Barber; Edison Johar; Benediktus Andries; Jeanne R Poespoprodjo; Enny Kenangalem; Kim A Piera; Anna Ehmann; Ric N Price; Timothy William; Tonia Woodberry; Simon Foote; Gabriela Minigo; Tsin W Yeo; Matthew J Grigg; Nicholas M Anstey; Brendan J McMorran Journal: Blood Date: 2018-07-19 Impact factor: 25.476
Authors: Sumudu Britton; Qin Cheng; Matthew J Grigg; Catherine B Poole; Cielo Pasay; Timothy William; Kimberley Fornace; Nicholas M Anstey; Colin J Sutherland; Chris Drakeley; James S McCarthy Journal: PLoS Negl Trop Dis Date: 2016-02-12